Artificial Intelligence

Echo AI Improves LVEF Workflow and Variability

Cedars-Sinai researchers published what might be the strongest evidence yet of AI’s ability to improve echocardiography workflows and accuracy.

The researchers randomized 3,495 transthoracic echo LVEF studies to be assessed by either a Cedars-Sinai-developed AI tool or expert sonographers (within the standard cardiology PACS workflow), before final assessments by blinded cardiologists.

This was the first blinded RCT evaluating an echo AI solution, and one of the first for any imaging AI solutions.

Echo AI nailed the study’s primary endpoint, as the final cardiologist assessments required substantial LVEF changes (>5% change) far less often with AI-based studies than those from the sonographer group (16.8% vs. 27.2%).

The echo AI solution AI further supported its advantage over sonographer assessments, producing…

  • A smaller average LVEF difference between the initial and final cardiologist assessments (2.79% vs. 3.77%)
  • A smaller average LVEF difference between the final cardiologist assessments and patients’ previous/historical cardiologist assessments (6.29% vs. 7.23%)
  • Faster average initial LVEF assessments (AI 131 seconds faster)
  • Faster median cardiologist LVEF assessments (54 vs. 64 seconds)

The blinded cardiologists also often couldn’t tell whether AI or the human sonographers produced the initial assessments (43%), while predicting the correct assessment source only slightly more often than the incorrect source (32% & 24%).

The Takeaway

This study shows that AI-based LVEF assessments can be “non-inferior and even superior” to initial assessment by sonographers, while also reducing labor and variability throughout the echo workflow. 

Even though previous echo AI research has produced similar results and this study only used data from a single center, the fact that it was echo AI’s first blinded RCT is very notable, and bolsters the growing body of evidence supporting AI’s ability to improve echo workflows in the real world.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]